Literature DB >> 26240428

A neurocognitive model for understanding treatment action in depression.

Matthew B Warren1, Abbie Pringle1, Catherine J Harmer2.   

Abstract

The way in which emotion is represented and processed in the human brain is an expanding area of research and has key implications for how we understand and potentially treat affective disorders such as depression. Characterizing the effects of pharmacological manipulations of key neurotransmitter systems can also help reveal the neurochemical underpinnings of emotional processing and how common antidepressant drugs may work in the treatment of depression and anxiety. This approach has revealed that depression is associated with both neural and behavioural biases towards negative over positive stimuli. Evidence from pharmacological challenge studies suggests that antidepressant treatment acts to normalize these biases early on in treatment, resulting in patients experiencing the world in a more positive way, improving their mood over time. This model is supported by evidence from both pharmacological and non-pharmacological interventions. The unique perspective on antidepressant treatment offered by this approach provides some insights into individual response to treatment, as well as novel approaches to drug development.
© 2015 The Author(s) Published by the Royal Society. All rights reserved.

Entities:  

Keywords:  depression; emotional processing; neuroimaging

Mesh:

Substances:

Year:  2015        PMID: 26240428      PMCID: PMC4528825          DOI: 10.1098/rstb.2014.0213

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN: 0962-8436            Impact factor:   6.237


  103 in total

1.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

Authors:  Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

2.  Short-term antidepressant administration reduces negative self-referential processing in the medial prefrontal cortex in subjects at risk for depression.

Authors:  M Di Simplicio; R Norbury; C J Harmer
Journal:  Mol Psychiatry       Date:  2011-03-01       Impact factor: 15.992

3.  Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing.

Authors:  Jamie Horder; Michael Browning; Martina Di Simplicio; Philip J Cowen; Catherine J Harmer
Journal:  J Psychopharmacol       Date:  2011-03-15       Impact factor: 4.153

4.  The regional cerebral blood flow changes in major depressive disorder with and without psychotic features.

Authors:  Ali Saffet Gonul; Mustafa Kula; Arzu Guler Bilgin; Ahmet Tutus; Aslan Oguz
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2004-09       Impact factor: 5.067

5.  NK1 receptor antagonism and emotional processing in healthy volunteers.

Authors:  P Chandra; S Hafizi; R M Massey-Chase; G M Goodwin; P J Cowen; C J Harmer
Journal:  J Psychopharmacol       Date:  2009-04-07       Impact factor: 4.153

6.  Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition.

Authors:  Catherine J Harmer; Nicholas C Shelley; Philip J Cowen; Guy M Goodwin
Journal:  Am J Psychiatry       Date:  2004-07       Impact factor: 18.112

7.  Short-term serotonergic but not noradrenergic antidepressant administration reduces attentional vigilance to threat in healthy volunteers.

Authors:  Susannah E Murphy; Jenny Yiend; Kathryn J Lester; Philip J Cowen; Catherine J Harmer
Journal:  Int J Neuropsychopharmacol       Date:  2008-08-28       Impact factor: 5.176

8.  Agomelatine facilitates positive versus negative affective processing in healthy volunteer models.

Authors:  Catherine J Harmer; Christian de Bodinat; Gerard R Dawson; Colin T Dourish; Lara Waldenmaier; Sally Adams; Philip J Cowen; Guy M Goodwin
Journal:  J Psychopharmacol       Date:  2010-07-21       Impact factor: 4.153

9.  Neural responses to happy facial expressions in major depression following antidepressant treatment.

Authors:  Cynthia H Y Fu; Steve C R Williams; Michael J Brammer; John Suckling; Jieun Kim; Anthony J Cleare; Nicholas D Walsh; Martina T Mitterschiffthaler; Chris M Andrew; Emilio Merlo Pich; Edward T Bullmore
Journal:  Am J Psychiatry       Date:  2007-04       Impact factor: 18.112

10.  Short-term SSRI treatment normalises amygdala hyperactivity in depressed patients.

Authors:  B R Godlewska; R Norbury; S Selvaraj; P J Cowen; C J Harmer
Journal:  Psychol Med       Date:  2012-04-25       Impact factor: 7.723

View more
  15 in total

1.  Differential change on depressive symptom factors with antidepressant medication and cognitive behavior therapy for major depressive disorder.

Authors:  Boadie W Dunlop; Steven P Cole; Charles B Nemeroff; Helen S Mayberg; W Edward Craighead
Journal:  J Affect Disord       Date:  2017-12-27       Impact factor: 4.839

2.  Attentional bias modification is associated with fMRI response toward negative stimuli in individuals with residual depression: a randomized controlled trial

Authors:  Eva Hilland; Nils I. Landrø; Catherine J. Harmer; Michael Browning; Luigi A. Maglanoc; Rune Jonassen
Journal:  J Psychiatry Neurosci       Date:  2020-01-01       Impact factor: 6.186

3.  Changing the Way We Think About (and With) Antidepressants.

Authors:  Andrew M Novick; David A Ross
Journal:  Biol Psychiatry       Date:  2018-08-15       Impact factor: 13.382

4.  Changes in causal attributions and relationship representations: Are they specific or common mechanisms in the treatment of depression?

Authors:  Sigal Zilcha-Mano; Harold Chui; Tohar Dolev; Kevin S McCarthy; Ulrike Dinger; Jacques P Barber
Journal:  J Affect Disord       Date:  2015-12-31       Impact factor: 4.839

5.  Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression.

Authors:  J B Stroud; T P Freeman; R Leech; C Hindocha; W Lawn; D J Nutt; H V Curran; R L Carhart-Harris
Journal:  Psychopharmacology (Berl)       Date:  2017-10-30       Impact factor: 4.530

6.  Selective serotonin reuptake inhibitor treatment retunes emotional valence in primate ventral striatum.

Authors:  Benjamin Pasquereau; Guillaume Drui; Yosuke Saga; Augustin Richard; Mathilde Millot; Elise Météreau; Véronique Sgambato; Philippe N Tobler; Léon Tremblay
Journal:  Neuropsychopharmacology       Date:  2021-03-10       Impact factor: 7.853

7.  Understanding the brain by controlling neural activity.

Authors:  Kristine Krug; C Daniel Salzman; Scott Waddell
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-09-19       Impact factor: 6.237

Review 8.  Innovative approaches to bipolar disorder and its treatment.

Authors:  Paul J Harrison; Andrea Cipriani; Catherine J Harmer; Anna C Nobre; Kate Saunders; Guy M Goodwin; John R Geddes
Journal:  Ann N Y Acad Sci       Date:  2016-02       Impact factor: 5.691

9.  Controlling the Emotional Bias: Performance, Late Positive Potentials, and the Effect of Anodal Transcranial Direct Current Stimulation (tDCS).

Authors:  Florian Faehling; Christian Plewnia
Journal:  Front Cell Neurosci       Date:  2016-06-17       Impact factor: 5.505

10.  Effects of Buprenorphine on Responses to Emotional Stimuli in Individuals with a Range of Mood Symptomatology.

Authors:  Anya K Bershad; Nicholas A Ruiz; Harriet de Wit
Journal:  Int J Neuropsychopharmacol       Date:  2018-02-01       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.